Application of PET and PEt/CT imaging for cancer screening.

The aim of this study was to evaluate the potential application of 18-fluorodeoxyglucose positron emission tomography (FDG PET) and PET/CT for cancer screening in asymptomatic individuals. The subjects consisted of 3631 physical check-up examinees (1947 men, 1684 women; mean age +/- SD, 52.1 +/- 8.2 y) with non-specific medical histories. Whole-body FDG PET (or PET/CT), ultrasound and tumor markers were performed on all patients. Focal hypermetabolic areas with intensities equal to or exceeding the level of FDG uptake in the brain were considered abnormal and interpreted as neoplasia. Follow-up periods were longer than one year. Among the 3631 FDG PET (including 1687 PET/CT), ultrasound and tumor markers examinations, malignant tumors were discovered in 47 examinees (1.29%). PET findings were true-positive in 38 of the 47 cancers (80.9%). In addition, 32 of the 47 cancers were screened with the PET/CT scan. PET detected cancer lesions in 28 of the 32 examinees. However, the CT detected cancer lesions in only 15 out of 32 examinees. The sensitivity of FDG PET in the detection of a wide variety of cancers is high. Most cancer can be detected with FDG PET at a resectable stage. CT of the PET/CT for localization and characteristics of the lesion showed an increased specificity of the PET scan. The use of ultrasound and tumor markers may complement the PET scan in cancer screening for hepatic and urologic neoplasms.

[1]  M. Mukai,et al.  Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. , 2000, Oncology reports.

[2]  B J McNeil,et al.  CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. , 1991, Radiology.

[3]  S. Yasuda,et al.  Application of positron emission tomography imaging to cancer screening , 2000, British Journal of Cancer.

[4]  Y. Shen,et al.  The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. , 2003, Neoplasma.

[5]  S. Sone,et al.  Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner , 2001, British Journal of Cancer.

[6]  L. Tabár.  Control of breast cancer through screening mammography. , 1990, Radiology.

[7]  G. Murphy,et al.  UICC meeting on breast‐cancer screening in pre‐menopausal women in developed countries , 1994, Cancer.

[8]  S. Armato,et al.  Lung cancers missed at low-dose helical CT screening in a general population: comparison of clinical, histopathologic, and imaging findings. , 2002, Radiology.

[9]  M. Spieth,et al.  A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  D Delbeke,et al.  Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  H. Abdel-Nabi,et al.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. , 1998, Radiology.

[12]  N. Williams,et al.  COLONOSCOPY OR BARIUM ENEMA AS INITIAL INVESTIGATION OF COLONIC DISEASE , 1987, The Lancet.

[13]  D. Noh,et al.  Diagnostic Value of Positron Emission Tomography for Detecting Breast Cancer , 1998, World Journal of Surgery.

[14]  W. Oyen,et al.  Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings , 2001, European Journal of Nuclear Medicine.

[15]  O. Miettinen,et al.  Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.

[16]  M. Brant-Zawadzki.  CT screening: why I do it. , 2002, AJR. American journal of roentgenology.

[17]  P. M. Falk,et al.  Positron emission tomography for preoperative staging of colorectal carcinoma , 1994, Diseases of the colon and rectum.